Novel conditionally active T cell engagers sourced from proprietary BiTAC® platform are at the basis of advanced partnering initiatives and development activitiesZURICH, SWITZERLAND – July 6, 2026 -- ...
The "Diabetic Retinopathy - Pipeline Insight, 2026" report highlights growth opportunities with over 50 companies and 55 drugs in development across varied stages. Key prospects include advancing anti ...
First Patient Receives New Shield Surface Modification, An Advance in Flow Diversion Therapy, at NYU Langone Health Celebrating its 10-year anniversary in the U.S. in 2021, Pipeline Flex Embolization ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results